The BMJ Interview - Andrew Pollard on the Oxford/Astra Zeneca vaccine - podcast episode cover

The BMJ Interview - Andrew Pollard on the Oxford/Astra Zeneca vaccine

Jan 14, 202145 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Andrew Pollard is Director of the Oxford Vaccines Group - who, along with Astra Zeneca, have developed an modified adenovirus vaccine for SARS-CoV-2. In this interview we talk to him about the development of that vaccine - what he thinks about the UK government's plan to increase the interval between doses; if he worries about a mutating virus and vaccine escape; and how the university came to make a deal with a commercial company to provide cost-price vaccinations for the world.

www.bmj.com/coronavirus

For the best experience, listen in Metacast app for iOS or Android
Open in Metacast
The BMJ Interview - Andrew Pollard on the Oxford/Astra Zeneca vaccine | Medicine and Science from The BMJ podcast - Listen or read transcript on Metacast